Insider · CIK 0001606030
Anthony Hunt
director
Files at RGEN (REPLIGEN CORP), BLFS (BIOLIFE SOLUTIONS INC), MASS (908 Devices Inc.). First filing Nov 22, 2024, latest May 16, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $11M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RGEN: REPLIGEN CORP
RGENOct 9, 2026 · close 173.88
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | REPLIGEN CORP | $3.3M 26,447 shares | -19% | +13% from low-29% from high | |
| 10Weak | REPLIGEN CORP | $4.1M 26,756 shares | -16% | - | |
| 30Weak | RGENsell REPLIGEN CORP | $3.4M 24,246 shares | -15% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | BLFS BIOLIFE SOLUTIONS INC | DDisposition to issuer Common Stock | -15,046 | - | - | 0 | 4 d ago |
| Jun 11, 2025 | MASS 908 Devices Inc. | MOption exercise Common Stock | +11,364 | - | - | 30,085 | Jun 13, 2025 |
| Jun 11, 2025 | MASS 908 Devices Inc. | MOption exercise Restricted Stock Unitsderivative | -11,364 | $0.00 | $0 | 0 | Jun 13, 2025 |
| Jun 12, 2025 | MASS 908 Devices Inc. | AGrant or award Restricted Stock Unitsderivative | +14,083 | $0.00 | $0 | 14,083 | Jun 13, 2025 |
| Jun 12, 2025 | MASS 908 Devices Inc. | AGrant or award Stock Option (option to buy)derivative | +6,516 | $0.00 | $0 | 6,516 | Jun 13, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -2,043 | $122.66 | $251k | 134,258 | May 16, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -17,596 | $123.57 | $2.2M | 116,662 | May 16, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -6,533 | $124.34 | $812k | 110,129 | May 16, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -268 | $125.20 | $34k | 109,861 | May 16, 2025 |
| May 15, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -7 | $127.00 | $889 | 109,854 | May 16, 2025 |
| Mar 18, 2025 | BLFS BIOLIFE SOLUTIONS INC | AGrant or award Common Stock | +6,876 | - | - | 6,876 | Mar 20, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | MOption exercise Common Stock10b5-1 | +5,000 | $33.87 | $169k | 141,301 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | MOption exercise Common Stock10b5-1 | +21,756 | $59.52 | $1.3M | 163,057 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -60 | $148.05 | $8,883 | 162,997 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -100 | $150.38 | $15k | 162,897 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -2,518 | $151.09 | $380k | 160,379 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -6,176 | $151.96 | $939k | 154,203 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -15,619 | $152.82 | $2.4M | 138,584 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock10b5-1 | -2,283 | $153.70 | $351k | 136,301 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 202,344 | Mar 19, 2025 |
| Mar 17, 2025 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -21,756 | $0.00 | $0 | 0 | Mar 19, 2025 |
| Mar 3, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -10,142 | $155.38 | $1.6M | 136,301 | Mar 4, 2025 |
| Mar 2, 2025 | MASS 908 Devices Inc. | MOption exercise Common Stock | +2,058 | - | - | 18,721 | Mar 4, 2025 |
| Mar 2, 2025 | MASS 908 Devices Inc. | MOption exercise Restricted Stock Unitsderivative | -2,058 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Feb 27, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -2,825 | $156.54 | $442k | 146,443 | Feb 28, 2025 |
| Feb 24, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -2,380 | $164.74 | $392k | 149,268 | Feb 25, 2025 |
| Dec 5, 2024 | RGEN REPLIGEN CORP | MOption exercise Common Stock | +11,808 | $33.87 | $400k | 151,648 | Dec 5, 2024 |
| Dec 5, 2024 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative | +11,808 | $0.00 | $0 | 8,856 | Dec 5, 2024 |
| Nov 21, 2024 | RGEN REPLIGEN CORP | MOption exercise Common Stock | +24,246 | $33.87 | $821k | 164,086 | Nov 22, 2024 |
| Nov 21, 2024 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock | -24,246 | $139.67 | $3.4M | 139,840 | Nov 22, 2024 |
| Nov 21, 2024 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative | +24,246 | $0.00 | $0 | 0 | Nov 22, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.